Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase

  • Bioorg Med Chem Lett. 2008 Aug 1;18(15):4352-4. doi: 10.1016/j.bmcl.2008.06.072.
Zachary K Sweeney  1 ,  James P Dunn ,  Yu Li ,  Gabrielle Heilek ,  Pete Dunten ,  Todd R Elworthy ,  Xiaochun Han ,  Seth F Harris ,  Donald R Hirschfeld ,  J Heather Hogg ,  Walter Huber ,  Ann C Kaiser ,  Denis J Kertesz ,  Woongki Kim ,  Taraneh Mirzadegan ,  Michael G Roepel ,  Y David Saito ,  Tania M P C Silva ,  Steven Swallow ,  Jahari L Tracy ,  Armando Villasenor ,  Harit Vora ,  Amy S Zhou ,  Klaus Klumpp
Affiliations
  • 1. Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, CA 94304, USA. [email protected]
PMID: 18632268 DOI: 10.1016/j.bmcl.2008.06.072
Abstract

A series of benzyl pyridazinones were evaluated as HIV-1 non-nucleoside Reverse Transcriptase inhibitors (NNRTIs). Several members of this series showed good activity against the wild-type virus and NNRTI-resistant viruses. The binding of inhibitor 5a to HIV-RT was analyzed by surface plasmon resonance spectroscopy. Pharmacokinetic studies of 5a in rat and dog demonstrated that this compound has good oral bioavailability in animal species. The crystal structure of a complex between HIV-RT and inhibitor 4c is also described.